These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35078243)

  • 41. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
    Nakayama I; Takahari D; Chin K; Wakatsuki T; Takamatsu M; Yamamoto N; Ogura M; Ooki A; Fukuda K; Osumi H; Fukuoka S; Shinozaki E; Yamaguchi K
    ESMO Open; 2023 Aug; 8(4):101582. PubMed ID: 37348349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer.
    Haverkamp L; Seesing MF; Ruurda JP; Boone J; V Hillegersberg R
    Dis Esophagus; 2017 Jan; 30(1):1-7. PubMed ID: 27001442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Petrackova A; Savara J; Turcsanyi P; Gajdos P; Papajik T; Kriegova E
    Br J Haematol; 2022 Nov; 199(3):371-381. PubMed ID: 36029002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
    Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
    Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
    Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
    Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.
    Li-Chang HH; Kasaian K; Ng Y; Lum A; Kong E; Lim H; Jones SJ; Huntsman DG; Schaeffer DF; Yip S
    BMC Cancer; 2015 Feb; 15():32. PubMed ID: 25656989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The genomic landscape of oesophagogastric junctional adenocarcinoma.
    Chong IY; Cunningham D; Barber LJ; Campbell J; Chen L; Kozarewa I; Fenwick K; Assiotis I; Guettler S; Garcia-Murillas I; Awan S; Lambros M; Starling N; Wotherspoon A; Stamp G; Gonzalez-de-Castro D; Benson M; Chau I; Hulkki S; Nohadani M; Eltahir Z; Lemnrau A; Orr N; Rao S; Lord CJ; Ashworth A
    J Pathol; 2013 Nov; 231(3):301-10. PubMed ID: 24308032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction.
    Lagarde SM; ten Kate FJ; Richel DJ; Offerhaus GJ; van Lanschot JJ
    Ann Surg Oncol; 2007 Feb; 14(2):977-91. PubMed ID: 17122988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spectrum of genetic changes in gastro-esophageal cancer cell lines determined by an integrated molecular cytogenetic approach.
    Rosenberg C; Geelen E; IJszenga MJ; Pearson P; Tanke HJ; Dinjens WN; van Dekken H
    Cancer Genet Cytogenet; 2002 May; 135(1):35-41. PubMed ID: 12072201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes.
    Geng Q; Lao J; Zuo X; Chen S; Bei JX; Xu D
    J Pathol; 2020 Nov; 252(3):263-273. PubMed ID: 32715475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer.
    Mullen JT; Kwak EL; Hong TS
    Ann Surg Oncol; 2016 Nov; 23(12):3780-3785. PubMed ID: 27459983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma.
    Gao XS; Qiao X; Wu F; Cao L; Meng X; Dong Z; Wang X; Gao G; Wu TT; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):389-96. PubMed ID: 17236963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endoscopic Characteristics of Early Gastroesophageal Junction Adenocarcinomas and Assessment for Invasion Depth: A Case Series Study.
    Song S; Yan F; Zhang J; Gong A
    Turk J Gastroenterol; 2024 Jan; 35(1):11-16. PubMed ID: 38454273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients.
    Huang Q; Fan X; Agoston AT; Feng A; Yu H; Lauwers G; Zhang L; Odze RD
    Histopathology; 2011 Aug; 59(2):188-97. PubMed ID: 21884197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
    Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
    Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.